Table of Contents
Denied party screening biotech teams cannot skip. The reason is simple. Biotech sits on top of dual-use goods, sensitive technology, and a global web of partners. That mix draws heavy attention from export regulators. One wrong shipment, license, or lab hire can trigger a real penalty.
This guide explains how screening works for a biotech company. It covers the lists you check, who you screen, and the edge cases that catch labs off guard. For the wider basics, start with the denied party screening hub, then come back here for the biotech detail.
What denied party screening means for biotech
Denied party screening is the check you run before you deal with anyone. You compare a name against government watch lists. The goal is to catch people and companies the government has blocked. If someone is on a list, you stop and dig deeper before you act. New to the idea? Read denied party screening 101 first.
Biotech carries more risk than most industries. Many products count as dual-use. That means the same reagent, sequencer, or bioprocess tool can serve medicine or a weapons program. Regulators watch these closely. Your customer base is also global. You ship to research labs, hospitals, and distributors across many countries. Each of those parties needs a check.
The lists you screen against
Several U.S. agencies keep watch lists. Biotech firms touch most of them. The fastest way to check the U.S. lists in one place is the government’s Consolidated Screening List. It pulls together the main lists from Commerce, State, and Treasury.
| List | Agency | Why biotech cares |
|---|---|---|
| SDN List | OFAC (Treasury) | Blocks sanctioned people and firms. A full trade ban applies. |
| Entity List | BIS (Commerce) | Names labs and firms with license rules. Many are research bodies. |
| Denied Persons List | BIS (Commerce) | People stripped of export rights. No exports allowed. |
| Unverified List | BIS (Commerce) | Parties BIS could not verify. Extra due diligence needed. |
| Military End User List | BIS (Commerce) | Flags military-linked buyers of dual-use items. |
The BIS Entity List matters a lot in biotech. Regulators have added research institutes tied to gene work and biotech programs. The OFAC SDN List is the other big one. If a party sits on it, you cannot deal with them at all.
Do not stop at the U.S. lists. If you sell into Europe, check the EU sanctions list. If you touch the UK, check the OFSI list. The UN keeps a consolidated list too. A buyer clean in one country can be blocked in another.
Who you need to screen in a biotech workflow
Screening is not only for the buyer at the end. You check every party in the chain. Biotech chains are long and often global.
- Customers and distributors who resell your reagents or devices
- Suppliers of chemicals, cell lines, and lab equipment
- Contract research organizations that run studies for you
- Contract manufacturers who make your product
- Clinical trial sites and their principal investigators
- Academic and research collaborators abroad
- Freight forwarders and customs brokers
- Investors, board members, and joint venture partners
- New hires and visiting scientists at your labs
That last group surprises people. Screening a job applicant or a lab visitor is normal in biotech. It links to the deemed export rule, which we cover below. For a full map of who is in scope, see who needs to do denied party screening.
Deemed exports and foreign nationals
A deemed export is a rule that catches many biotech labs. You do not have to ship anything abroad. If you share controlled technology or source code with a foreign national inside the U.S., that counts as an export to their home country. A lab tour, a shared protocol, or training a new hire can all trigger it.
This is why biotech firms screen staff and visitors. You need to know a person’s nationality and check the technology they will touch. Some controlled biological items need a license before a foreign national can access them. Read what a deemed export is to see how the rule plays out on the ground.
The ownership trap: the 50 percent rule
A clean name is not always safe. OFAC applies the 50 percent rule. If one or more blocked parties own half or more of a company, that company is blocked too. It can be blocked even if its own name is not on any list.
Biotech deals often run through holding companies and joint ventures. A distributor may look fine on the surface. Its parent may be sanctioned. You need to check ownership, not just the name on the invoice. Learn how this works in the 50 percent rule in sanctions screening.
How to run a screening, step by step
- Collect the party’s full legal name, address, and country.
- Gather ownership details for companies and their parents.
- Run the name against the U.S. lists and any foreign lists that apply.
- Review every hit. Most are false positives from similar names.
- Confirm or clear each match with dates of birth, addresses, or IDs.
- Escalate a true match. Stop the deal and tell compliance.
- Save the search, the result, and your decision.
- Rescreen with each new order and when lists change.
Most alerts are not real. A common name can flag against a listed person who is not your buyer. You clear it by checking extra details. Never delete a hit without a note. For a deeper method, see how to resolve a false positive.
Biotech edge cases that catch labs out
Select agents and toxins
Some pathogens and toxins carry tight controls. Shipping them abroad often needs a license. You still screen the receiving lab and its people first. A license does not replace the party check.
Gene synthesis and sequence data
Sending synthetic DNA or sequence files can move controlled technology. Screen the requester and the destination. A customer ordering a flagged sequence deserves a closer look.
Clinical trials abroad
Trials in other countries add local sites, investigators, and vendors. Each is a party to screen. Do not assume the trial sponsor did it for you.
CROs and contract manufacturers
You may hand a molecule to a CRO or CDMO. They then work with their own subcontractors. Ask for their screening records. Their gap becomes your problem.
Manual checks or software
A small biotech can start with free tools. The Consolidated Screening List has a free search. That works for a low volume of parties. It does not scale, and it misses foreign lists and ownership data.
Screening software runs many lists at once. It re-checks your whole party base when lists change. It also stores an audit trail for you. As your deals grow, software pays off. Weigh both paths in automated vs manual denied party screening.
Records and audit trail
Screening is not done until you save proof. Regulators want to see that you checked. Keep the list version, the search date, the result, and the person who cleared it. U.S. export rules often ask you to hold records for five years.
Good records also protect you if a party is listed later. You can show you were clean at the time of the deal. See record keeping for denied party screening for what to store.
Frequently Asked Questions
Does a small biotech startup really need to screen?
Yes. The rules do not care about company size. A startup that ships a reagent abroad or hires a foreign national is in scope. The penalties are the same for a small firm as a large one.
How often should we rescreen our partners?
Screen at first contact and before each new transaction. Lists change almost every week. Many firms also run a full rescreen of all parties on a set schedule to catch new additions.
What is the difference between export controls and sanctions?
Export controls limit what you can send and to whom, often by license. Sanctions block dealings with specific people, firms, or countries. Biotech touches both. See the difference between export controls and sanctions.
Do we screen foreign nationals working in our U.S. lab?
Often yes. The deemed export rule treats sharing controlled tech with a foreign national as an export. You screen staff and visitors and check what technology they will access.
Key Takeaways
Biotech faces sharper screening risk than most sectors. Your products are often dual-use, and your partners span the globe. Check the U.S. lists plus foreign lists, and look at ownership under the 50 percent rule. Screen every party in the chain, including staff and visitors under the deemed export rule. Keep records for at least five years. When your volume grows, move from free tools to software. If you want help building a screening program for your lab, contact us.